idarucizumab is a monoclonal antibody fragment that works as a specific reversal agent for the anticoagulant dabigatran, a direct thrombin inhibitor used to prevent blood clot formation.
The action of idarucizumab binds with high affinity to dabigatran, thereby neutralizing its anticoagulant effects by forming an inactive complex that can be eliminated from the body. This rapid reversal effect can restore normal clotting parameters within minutes, making idarucizumab a valuable tool in emergencies where rapid reversal of dabigatran is needed, such as in cases of uncontrolled bleeding or emergency surgery.
The spectrum of idarucizumab is limited to reversing the anticoagulant effects of dabigatran only, and it does not affect other anticoagulants or coagulation factors. It is important tonote that idarucizumab should only be used in emergencies and under the supervision of a healthcare professional, as its use can lead to an increased risk of thromboembolic events.